Next Article in Journal
Cognitive Effects of Toxoplasma and CMV Infections: A Cross-Sectional Study of 557 Young Adults Considering Modulation by Sex and Rh Factor
Previous Article in Journal
Hepatitis Delta Virus and Hepatocellular Carcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 13
Issue 5
10.3390/pathogens13050364
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Role of Prevotella species in Female Genital Tract Infections

by
Sheridan D. George
1,*,
Olivia T. Van Gerwen
1,
Chaoling Dong
1,
Lúcia G. V. Sousa
2,
Nuno Cerca
2,
Jacob H. Elnaggar
3,
Christopher M. Taylor
3 and
Christina A. Muzny
1
1
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
2
Centre of Biological Engineering (CEB), Laboratory of Research in Biofilms Rosário Oliveira (LIBRO), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal
3
Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
*
Author to whom correspondence should be addressed.
Pathogens 2024, 13(5), 364; https://doi.org/10.3390/pathogens13050364
Submission received: 4 April 2024 / Revised: 25 April 2024 / Accepted: 26 April 2024 / Published: 28 April 2024
Browse Figures
Versions Notes

Abstract

:
Female genital tract infections (FGTIs) include vaginal infections (e.g., bacterial vaginosis [BV]), endometritis, pelvic inflammatory disease [PID], and chorioamnionitis [amniotic fluid infection]. They commonly occur in women of reproductive age and are strongly associated with multiple adverse health outcomes including increased risk of HIV/sexually transmitted infection acquisition and transmission, infertility, and adverse birth outcomes such as preterm birth. These FGTIs are characterized by a disruption of the cervicovaginal microbiota which largely affects host immunity through the loss of protective, lactic acid-producing Lactobacillus spp. and the overgrowth of facultative and strict anaerobic bacteria. Prevotella species (spp.), anaerobic Gram-negative rods, are implicated in the pathogenesis of multiple bacterial FGTIs. Specifically, P. bivia, P. amnii, and P. timonensis have unique virulence factors in this setting, including resistance to antibiotics commonly used in treatment. Additionally, evidence suggests that the presence of Prevotella spp. in untreated BV cases can lead to infections of the upper female genital tract by ascension into the uterus. This narrative review aims to explore the most common Prevotella spp. in FGTIs, highlight their important role in the pathogenesis of FGTIs, and propose future research in this area.

1. Introduction

Bacterial female genital tract infections (FGTIs) are characterized by vaginal dysbiosis as a result of an increase in microbial diversity [1]. This is commonly due to the replacement of protective vaginal Lactobacillus spp. by facultative and strict anaerobic bacteria [1,2,3]. Bacterial FGTIs include bacterial vaginosis (BV), endometritis, pelvic inflammatory disease (PID), and chorioamnionitis (amniotic fluid infection). They are all common in reproductive-age women (i.e., 12–45 years) [2,4,5] and can lead to multiple adverse health outcomes such as an increased risk of HIV/sexually transmitted infection (STI) acquisition and transmission, infertility, and adverse birth outcomes such as preterm birth [4].
BV, the most common vaginal infection, is the most common FGTI, affecting approximately 30% of reproductive-age women [2,6]. Untreated BV can lead to infections of the upper genital tract in women including endometritis, PID, and chorioamnionitis [2,7,8,9]. Furthermore, BV treatment alone incurs an estimated $4.8 billion per year in global healthcare costs, proving FGTIs to be a major global public health concern [6].
Endometritis is an inflammation of the endometrium [10] while PID causes the inflammation of the uterus, Fallopian tubes, and/or ovaries [11]. PID commonly occurs in the setting of endometritis, making its prevalence difficult to determine; however, PID is estimated to affect about 8% of women [10,12]. Chorioamnionitis is an infection of the amniotic fluid which occurs in about 4% of deliveries, although its incidence can increase in women with BV and/or STIs [13,14]. The prevalence of these FGTIs can also vary based on race, ethnicity, socioeconomic class, education, and other individual (i.e., sexual behaviors, smoking, etc.) and societal factors (i.e., access to healthcare) [15,16,17,18,19].
The vaginal microbiota is the cornerstone of vaginal health, representing a complex and dynamic relationship among many bacterial species (spp.) [20]. Lactobacillus spp. are the predominant micro-organisms in most women with an optimal vaginal microbiota, maintaining an acidic environment that is protective against BV and STIs [20]. Fluctuations of the vaginal microbiota can occur during different stages in a woman’s life such as puberty, menses, pregnancy, and menopause [21,22,23]. However, regardless of a woman’s life stage, vaginal dysbiosis can occur [24]. The disruption of the healthy vaginal microbiota is associated with an increased risk of FGTIs with detrimental public health implications [23]. Notably, it is unknown whether anaerobic bacteria cause the loss or displacement of Lactobacillus spp. but it is a proposed step in some FGTI etiologies such as BV [25]; other studies have found that Lactobacillus phages could also play a role [26,27]. Regardless, the loss or displacement of the protective lactic acid-producing lactobacilli encourages FGTI-associated bacteria, such as Prevotella spp., to colonize the vaginal epithelium [28,29].
Prevotella spp. are an important constituent of the vaginal microbiota in many FGTIs [2,10,21,30]. They are Gram-negative, obligate anaerobes commonly found in the human vaginal microbiota as well as in the gastrointestinal tract, respiratory tract, and oral cavity [31]. Characterized in 1990 from the genus Bacteroides, Prevotella spp. are differentiated as non-motile, non-spore-forming rods with their color ranging from shiny white to black colonies [32,33,34]. As of 2024, there are over 57 publicly known species of Prevotella, most of which are integrated into the human microbiome [33]. For the purposes of this review, only the 48 well-characterized Prevotella spp. found in humans will be discussed (Table 1). There are many culture-independent laboratory techniques used to detect Prevotella spp. such as quantitative polymerase chain reaction (qPCR), 16S ribosomal ribonucleic acid (16S rRNA) gene sequencing, shotgun metagenomic sequencing, and fluorescent in situ hybridization (FISH) (Figure 1) [35,36].
Exploring the role of Prevotella spp. in FGTIs may reveal new mechanisms of BV, endometritis, PID, and chorioamnionitis pathogenesis. The purpose of this narrative review is to discuss the roles of key vaginal Prevotella spp. in relation to vaginal dysbiosis, BV, and other FGTIs, discuss the public health implications of infection with these micro-organisms, and propose future research needed to better understand their roles in FGTIs.

2. Key Vaginal Prevotella spp. in FGTIs

As previously mentioned, Prevotella spp. are commonly found in multiple FGTIs [2,49] including BV, endometritis, PID, and chorioamnionitis [2,43,49]. The most prevalent Prevotella spp. that can be found in the vaginal microbiota are P. bivia, P. amnii, and P. timonensis [28,38]. These three species are implicated as constituents of FGTIs with varying virulence factors and roles during infection [28,38]. By far, P. bivia is the most well-studied and most commonly found Prevotella spp. in the female genital tract [68].

2.1. Prevotella bivia

P. bivia is characterized by small, gray colonies which produce sialidase and ammonia (Figure 2, Table 2) [69]. P. bivia was first isolated and classified from clinical isolates, many of which originated from the female genital tract such as transabdominal hysterectomy tissue, peritoneal fluid (in a patient with PID), blood from a septic abortion, a cervical-vaginal swab, and vaginal discharge [70]. P. bivia is strongly associated with FGTIs, primarily BV, more so than other Prevotella spp. [29,71]. P. bivia is hypothesized as a key biofilm colonizer early into BV infection, joining the biofilm after Gardnerella spp. to create a commensal and persistent relationship [69]. In vitro, P. bivia is able to incorporate into G. vaginalis biofilms accounting for ~38% of the total biomass [72]. In infected mice, P. bivia persisted longer and at a higher density than G. vaginalis, despite being inoculated at a lower dosage [73]. In one cohort study, 47% of the women with BV had P. bivia present using conventional culture methods [74]. In scanning electron microscopy images, P. bivia appears as dispersed biofilms and exhibits crevice colonization during endometrial epithelial tissue infection [28]. Plummer et al. have also suggested that key taxa/spp., particularly P. bivia, could have a role in BV recurrence [75].

2.2. Prevotella amnii

P. amnii was first isolated from infected amniotic fluid and is characterized as small, circular, white colonies on blood agar [37]. Of Prevotella spp., P. amnii has the smallest genome of just 2.37 Mb [33]. P. amnii is found in the female reproductive tract and is associated with BV, endometritis, and PID [28,38,39,40]. It can co-occur with C. trachomatis infection, and both P. amnii and P. timonensis have been identified as possible C. trachomatis infection biomarkers [33,82]. In one study of women with C. trachomatis infection, the prevalence of P. amnii was 3.2% while in women without C. trachomatis, its prevalence was much lower (0.001%) [82]. In another study of women at risk for chlamydial cervicitis, P. amnii was found in 59% of the women who subsequently developed PID compared to 24% of the women who did not [38]. In a spontaneous preterm birth study, P. amnii was found to be significantly associated with preterm birth, while P. bivia, P. timonensis, and other Prevotella spp. were not [83]. Although P. amnii is understudied, its presence could signify adverse sequelae although more research is required to fully understand its role in this setting.

2.3. Prevotella timonensis

P. timonensis, originally isolated from a human breast abscess [76], is another abundant Prevotella spp. in FGTIs. While other Prevotella spp. can be found in women with and without BV (i.e., P. bivia, etc. [20]), P. timonensis is primarily only found in women with BV [84]. In a previous 16S rRNA sequencing study, P. timonensis has been found in 76% of the women with BV compared to only 9% of the women without BV [72]. Growth on blood agar is similar to both P. bivia and P. amnii but with slightly larger colonies of 1–2 mm (Table 2) [76]. Similar to P. amnii, P. timonensis can also co-occur in C. trachomatis infections [33,82]. P. timonensis is also associated with the persistence and slower regression of cervical intraepithelial neoplasia in women with high-risk human papillomavirus (HPV) subtypes [33,85].

3. Virulence Factors of Vaginal Prevotella spp.

Prevotella spp. were first identified to be dark-colored colonies with a moderate potential to break down carbohydrates with bile sensitivity [32]. Now, much more is known about their physiology, especially their virulence pathways and the mechanisms of action during infection. Prevotella spp. are known to have adhesins, fimbriae, and hemolysins and secrete nucleases, proteases, lipopolysaccharides (LPS), exopolysaccharides, and hydrolases [77,86,87]. Each of these virulence factors can lead to biofilm formation and antibiotic resistance [77].
During FGTIs, Prevotella spp. can secrete multiple products, such as hydrolases and ammonia, which can contribute to an increase in virulence [77,87]. Of these secreted hydrolases, sialidase, also known as neuraminidase, is a common enzyme secreted by Prevotella spp. (Table 3) [28,80,88]. Sialidase acts by degrading immunoglobins and mucins of host epithelial cells [86,88]. This degradation catalyzes sialic acids and allows bacterial adhesion to host epithelial cells, resulting in reduced immunity to pathogens [89]. In the vagina, sialidases promote the breakdown of the protective mucus layer, which leads to bacterial attachment and the release of carbon sources to facilitate bacterial growth [73,90]. G. vaginalis, a key BV-associated bacterium, is most known for its sialidase activity and adherence, but it is important to note that Prevotella spp. secrete sialidase as well [33,87]. Ammonia production is also a dominant characteristic of Prevotella spp., notably P. bivia, which has been found to support G. vaginalis growth in vitro [69,78]. P. bivia commonly appears and persists during FGTIs likely due to its resistance against antibiotics used to treat these infections [75,77]. Metronidazole, a common treatment for anaerobic bacterial infections in FGTIs, inhibits protein synthesis [91]. Three clinical metronidazole-resistant P. bivia strains have been found to harbor a mobile genetic element, encoding a novel nim gene, nimK, and a small efflux MDR transporter [81]. Although the presence of the nimK gene and the MDR transporter across multiple P. bivia isolates beyond the three isolates evaluated in this study is not yet known, P. bivia resistance to metronidazole could contribute to persistent infections, which may facilitate P. bivia ascension into the upper female genital tract [28,79,91].
Other Prevotella spp. beyond P. bivia also possess virulence factors. Previous 3D endometrial epithelial model studies have shown that P. amnii, P. buccae, P. corporis, P. denticola, P. disiens, P. histicola, and P. timonensis all produce sialidase, although P. timonensis produces more compared to the other species [28]. P. timonensis also had elongated microvilli wrapped around the surface of the 3D model, the greatest number of mucin degradation pathways, and interactions with vaginal dendritic cells which promote inflammation [28,33]. To date, these factors have not been shown in any other Prevotella spp. [28,33,77]. In this same endometrial epithelial model, P. disiens was significantly more cytotoxic to endometrial epithelial cells than other Prevotella spp., confirming its significant pathogenicity [28]. Many vaginal Prevotella spp. including P. bivia, P. amnii., and P. timonensis harbor clindamycin antibiotic resistance [46,79]. Each of these virulence mechanisms of Prevotella spp. could play key roles in the pathogenesis of FGTIs.

4. Role of Prevotella spp. in the Pathogenesis of BV

BV is characterized by the formation of a polymicrobial biofilm on vaginal epithelial cells [90]. Despite decades of extensive research, the etiology of BV remains controversial [92]. This has directly impacted improvements in the diagnosis, treatment, and prevention of this common vaginal infection [75,93]. With BV affecting up to 30% of reproductive-age women, a better understanding of its etiology will give critical insights into its management [7]. Prevotella spp. are commonly found in women with BV but their exact role in its pathogenesis remains unknown [94]. Prevotella spp. are part of the healthy vaginal microbiota, albeit in low numbers; however, their overgrowth is correlated with BV along with other anaerobic bacteria such as G. vaginalis and F. vaginae [29,92,94,95]. In a cohort of non-pregnant women with BV, Prevotella spp. represented 44% of all anaerobes isolated, suggesting their importance in BV infection [74].
In a study based on women who have sex with women (WSW), the mean relative abundance of P. bivia and G. vaginalis became sequentially higher 4 days (for P. bivia) and 3 days (for G. vaginalis) prior to the development of incident BV (iBV). This is compared to women who maintained normal vaginal microbiota during the study [71]. Based partly on the WSW study performed by Muzny et al., a conceptual model of BV pathogenesis was developed associating P. bivia and G. vaginalis with BV infection [69]. In this model, it is proposed that after the initial adhesion and displacement of vaginal lactobacilli by G. vaginalis, P. bivia attaches to the developing BV biofilm, prospers using amino acids produced by G. vaginalis for growth, and secretes ammonia [69,78]. The ammonia secreted by P. bivia enhances G. vaginalis growth, causing the biofilm to flourish [69,78]. The combined sialidase production of G. vaginalis and P. bivia breaks down the mucous layer and establishes an adherent biofilm [69]. This symbiotic relationship is thought to be essential in BV biofilm infection, adherence, and persistence [69,78].
In mouse models, P. bivia produced significant levels of sialidase during BV co-infection with G. vaginalis and alone, in vitro and in vivo [73]. Interestingly, P. bivia can colonize mice without G. vaginalis, even when inoculated in low doses [73]. In these mouse models, G. vaginalis co-cultured with P. bivia enhanced ascending uterine infection and invasion, supportive of an important role in the pathogenesis of upper FGTIs, such as endometritis and PID [49,73,96]. However, mice maintain a vaginal pH closer to seven and do not have a Lactobacillus spp. dominant vaginal microbiota like humans, which suggests that further studies are required to characterize this phenomenon in humans [73].
As previously mentioned, non-P. bivia spp. such as P. amnii, P. timonensis, P. corporis, and P. buccalis can also be found in women with BV [33]. There is mostly a genus-level focus on less prevalent Prevotella spp. sialidase and ammonia production, making it difficult to understand individual species’ involvement in biofilm formation. A recent study concluded that a higher relative abundance of Prevotella spp. remaining after BV treatment resulted in a higher likelihood of BV reoccurrence compared to women with a lower Prevotella spp. abundance [75]. These new data propose a potentially important role of Prevotella spp. in recurrent BV and high persistence rates even after treatment [75]. Untreated BV can lead to upper FGTIs such as endometritis and PID, suggesting why many Prevotella spp. are found in both lower and upper FGTIs (Table 1) [73].

5. Role of Prevotella spp. in the Pathogenesis of Endometritis and PID

Endometritis commonly co-occurs with PID, making it difficult to differentiate between the two conditions. Each can have a similar polymicrobial species composition including BVAB (BV-associated bacteria), Ureaplasma spp., Mycoplasma genitalium, etc. [10,97]. Because of this co-occurrence, endometritis is clinically underdiagnosed and statistically underrepresented in clinical and research settings [10,98]. Endometritis and PID have been closely associated with C. trachomatis and N. gonorrhoeae infections; however, studies have shown that at least half of the combined PID and endometritis cases have no trace of these bacterial STIs [99,100]. Interestingly, non-gonococcal, non-chlamydial PID caused by BVAB, such as Prevotella spp., is more prevalent than gonococcal/chlamydial PID, based on available data [49,101,102]. In a study of 545 participants with suspected PID, those with BVAB were more likely to have endometritis and recurrent PID than those without [97]. In another study of 278 women, those with acute endometritis were more likely to be infected with Gram-negative rods, such as P. bivia, along with having clinically diagnosed BV [49]. It is suggested that P. bivia could ascend from the vagina to the uterine cavity, causing endometritis and PID [103]. Most importantly, BVAB have been implicated in causing endometritis and PID individually from C. trachomatis or N. gonorrhoeae or any other FGTI-associated bacterial species [49].
As most women with PID are treated with antibiotics targeting chlamydia and/or gonorrhea, it has been suggested that a more effective treatment approach should also consider BVAB [49]. Petrina et al. tested endometrial biopsy isolates from women with PID and histologically confirmed endometritis cases with different antibiotic treatments after extraction in vitro [46]. After treatment with ceftriaxone, the only species remaining in the isolates were Prevotella spp. Prevotella spp. were susceptible to metronidazole while over half of the G. vaginalis present in the isolates were resistant, suggesting that several antibiotics could be required to clear endometritis and PID. Having notable resistance to ceftriaxone in vitro, Prevotella spp. could influence endometritis and PID case persistence and recurrence [46]. In another study testing different antibiotic efficacies for PID treatment, women with confirmed cases of PID were given common antibiotics prescribed for PID and chlamydia/gonorrhea (ceftriaxone and doxycycline) combined with metronidazole to compare to women given the same ceftriaxone and doxycycline treatment plus a placebo [104]. The women given ceftriaxone, doxycycline, and metronidazole had fewer endometrial anaerobic organisms and less pelvic discomfort than the placebo group at 1 month after treatment [104]. Because metronidazole is the recommended treatment for BV, this suggests that anaerobic bacteria (including Prevotella spp.) might also be playing a major role in PID cases [104]. This discovery has opened new questions in endometritis/PID research as well as a need to explore the role of Prevotella spp. in acute and chronic non-gonococcal, non-chlamydial endometritis/PID cases.
Of the many bacterial species implicated in PID, Prevotella spp. are found in half of the women with PID [46]. Of the three types of bacterial groups of PID, BVAB are associated with a 2-fold increased risk of PID [101,102]. In a study of women at risk for chlamydial cervicitis, the women with P. amnii were at an elevated risk of developing subsequent PID [38]. 16S rRNA samples from these same women also demonstrated that P. timonensis was the most prevalent bacterial species collected prior to PID development [38]. These data suggest that P. amnii and P. timonensis may be associated with an elevated risk of PID among high-risk women [38]. In addition, chronic PID can result in tubo-ovarian abscesses where Prevotella spp. predominate [105]. Prevotella spp. significantly contribute to the development of PID in women with and without STIs [38,49]. BVAB, particularly P. amnii and P. timonensis, are strongly associated with an increased risk of PID, regardless of the presence of STIs [38,49].
Because of the close association between endometritis and PID, additional research is necessary in women with endometritis alone as well as Prevotella spp.-specific involvement in this infection. Although there are difficulties in differentiating the cases of endometritis and PID, both conditions have a strong presence of BVAB including Prevotella spp. [46,104].

6. Role of Prevotella spp. in the Pathogenesis of Chorioamnionitis

Chorioamnionitis is a polymicrobial FGTI involving amniotic fluid during pregnancy or after delivery [13]. It is associated with multiple adverse health outcomes such as preterm birth, impaired infant brain development, chronic lung disease in infants, and, if left untreated, both maternal and infant mortality [13]. Prevotella spp., typically reported at the genus level, have been implicated in chorioamnionitis [106]. P. bivia is noted to be found in more serious cases of chorioamnionitis with high-grade inflammation and fetal vasculitis [43,96] and is associated with an increased risk of preterm birth [106,107]. P. bivia is found twice as often in severe cases of chorioamnionitis than in moderate cases [43], but its exact role is unknown. Other Prevotella spp. have not been specifically noted in women with chorioamnionitis to date; however, not many studies have explored this connection. More investigation is required to examine the relationship between Prevotella spp. and chorioamnionitis.

7. Future Areas of Research

Many FGTIs are dynamic, polymicrobial infections with complex etiologies. Many bacterial species have important roles in FGTIs, but Prevotella spp. possibly have the most questions unanswered. Because many FGTIs remain controversial in their exact etiology and pathophysiology, the knowledge gaps and research opportunities are plentiful in the field. The ultimate question of BV etiology still remains. Because BVAB are found in endometritis, PID, chorioamnionitis as well as other FGTIs, discovering the precise etiology of BV is key to treating and preventing many FGTIs. Also, the mechanism of how BV could cause other FGTIs like endometritis and PID is not fully understood or confirmed in humans. BV-associated endometritis, PID, and chorioamnionitis cases will likely remain a mystery until BV etiology is elucidated. Similarly, the exact role of Prevotella spp. in FGTIs is yet to be understood.
Many studies characterize Prevotella at the genus level only, leaving specific species involvement up for debate. P. bivia has been widely studied within the FGTI field, but P. amnii and P. timonensis deserve further attention. Ultimately, most Prevotella spp. require more attention to understand their roles in FGTIs as many appear at least in small quantities [38,49,83]. The interaction between BV, endometritis, PID, and chorioamnionitis infections requires more research on the specific mechanism of action of the bacterial species involved. More attention to Prevotella spp. in chorioamnionitis infection is needed, especially to investigate Prevotella spp. other than P. bivia. Current data suggest that Prevotella spp. influence complex relationships and bacterial ascension up the female genital tract to create environments for FGTIs to flourish [33,69,73].

8. Conclusions

Prevotella spp. are prevalent in FGTIs, notably P. bivia, P. amnii, and P. timonensis. BV, endometritis, PID, and chorioamnionitis all propose the importance of Prevotella spp. in their etiologies and the importance of focusing future investigations on Prevotella spp. during FGTIs. Critical gaps remain in the specifics of Prevotella spp. pathogenesis during infection. The unique virulence factors harbored by Prevotella spp. increase their ability to persist during infections, even after the use of certain antibiotics. FGTI treatment methods by testing the antibiotic resistance of BVAB isolates, such as Prevotella spp., could be necessary in recurrent and persistent FGTI cases. Advancing our understanding of the role of Prevotella spp. in FGTIs will improve diagnostic accuracy, treatment efficacy, and women’s health outcomes.

Author Contributions

S.D.G., O.T.V.G., C.D., L.G.V.S., N.C., J.H.E., C.M.T. and C.A.M. contributed to the conceptualization of this manuscript. S.D.G. and C.D. provided the figures. S.D.G., O.T.V.G., and C.A.M. prepared the original draft of the manuscript, and C.D., L.G.V.S., N.C., J.H.E., and C.M.T. revised and edited the manuscript accordingly. All authors have read and agreed to the published version of the manuscript.

Funding

This article was funded in part by R01AI146065-01, granted to author CAM by the National Institute of Allergy and Infectious Diseases (NIAID).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

Research reported in this publication was supported by the UAB High Resolution Imaging Facility.

Conflicts of Interest

O.T.V.G. has received research grant support from NIH, Abbott Molecular, Gilead Sciences, Inc, Visby, and Moderna, served on a scientific advisory board for Scynexis, and performed consulting for El Sevier, GSK, Abbott Molecular, and ThermoFisher for which she received honoraria. CAM has received research grant support to her institution from NIH/NIAID, Lupin Pharmaceuticals, Gilead Sciences, Inc., Visby Medical, and Abbott Molecular. She also reports honorarium and/or consulting fees from Scynexis, Cepheid, BioNTech, BioMed Diagnostics, Visby Medical, Elsevier, UpToDate, Abbott Molecular, and Roche. CMT has received research grant support to his institution from NIH/NIAID and reports consulting fees from Abbott Molecular.

References

  1. Han, Y.; Liu, Z.; Chen, T. Role of Vaginal Microbiota Dysbiosis in Gynecological Diseases and the Potential Interventions. Front. Microbiol. 2021, 12, 643422. [Google Scholar] [CrossRef] [PubMed]
  2. Ravel, J.; Moreno, I.; Simon, C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am. J. Obstet. Gynecol. 2021, 224, 251–257. [Google Scholar] [CrossRef] [PubMed]
  3. Moragianni, D.; Dryllis, G.; Andromidas, P.; Kapeta-Korkouli, R.; Kouskouni, E.; Pessach, I.; Papalexis, P.; Kodonaki, A.; Athanasiou, N.; Pouliakis, A.; et al. Genital tract infection and associated factors affect the reproductive outcome in fertile females and females undergoing in vitro fertilization. Biomed. Rep. 2019, 10, 231–237. [Google Scholar] [CrossRef] [PubMed]
  4. Ravel, J.; Brotman, R.M.; Gajer, P.; Ma, B.; Nandy, M.; Fadrosh, D.W.; Sakamoto, J.; Koenig, S.S.K.; Fu, L.; Zhou, X.; et al. Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. Microbiome 2013, 1, 29. [Google Scholar] [CrossRef] [PubMed]
  5. Ravel, J.; Gajer, P.; Abdo, Z.; Schneider, G.M.; Koenig, S.S.; McCulle, S.L.; Karlebach, S.; Gorle, R.; Russell, J.; Tacket, C.O.; et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. USA 2011, 108 (Suppl. 1), 4680–4687. [Google Scholar] [CrossRef] [PubMed]
  6. Peebles, K.; Velloza, J.; Balkus, J.E.; McClelland, R.S.; Barnabas, R.V. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex. Transm. Dis. 2019, 46, 304–311. [Google Scholar] [CrossRef] [PubMed]
  7. Morrill, S.R.; Agarwal, K.; Saha, S.; Lewis, W.G.; Gilbert, N.M.; Lewis, A.L. Models of Murine Vaginal Colonization by Anaerobically Grown Bacteria. J. Vis. Exp. 2022, 183, e64032. [Google Scholar] [CrossRef] [PubMed]
  8. Turpin, R.; Tuddenham, S.; He, X.; Klebanoff, M.A.; Ghanem, K.G.; Brotman, R.M. Bacterial Vaginosis and Behavioral Factors Associated With Incident Pelvic Inflammatory Disease in the Longitudinal Study of Vaginal Flora. J. Infect. Dis. 2021, 224, S137–S144. [Google Scholar] [CrossRef]
  9. Dingens, A.S.; Fairfortune, T.S.; Reed, S.; Mitchell, C. Bacterial vaginosis and adverse outcomes among full-term infants: A cohort study. BMC Pregnancy Childb. 2016, 16, 278. [Google Scholar] [CrossRef]
  10. Taylor, M.; Jenkins, S.M.; Pillarisetty, L.S. Endometritis; StatPearls: Treasure Island, FL, USA, 2023. [Google Scholar]
  11. Jennings, L.K.; Krywko, D.M. Pelvic Inflammatory Disease; StatPearls: Treasure Island, FL, USA, 2023. [Google Scholar]
  12. Singh, N.; Sethi, A. Endometritis-Diagnosis, Treatment and its impact on fertility—A Scoping Review. JBRA Assist. Reprod. 2022, 26, 538–546. [Google Scholar] [CrossRef]
  13. Fowler, J.R.; Simon, L.V. Chorioamnionitis; StatPearls: Treasure Island, FL, USA, 2023. [Google Scholar]
  14. Tita, A.T.N.; Andrews, W.W. Diagnosis and Management of Clinical Chorioamnionitis. Clin. Perinatol. 2010, 37, 339–354. [Google Scholar] [CrossRef] [PubMed]
  15. Diadhiou, M.; Ba Diallo, A.; Barry, M.S.; Alavo, S.C.; Mall, I.; Gassama, O.; Ndiaye Gueye, M.D.; Ndao Fall, A.; Gawa, E.; Gaye Diallo, A.; et al. Prevalence and Risk Factors of Lower Reproductive Tract Infections in Symptomatic Women in Dakar, Senegal. Infect. Dis. 2019, 12, 1178633719851825. [Google Scholar] [CrossRef] [PubMed]
  16. Kenyon, C.; Colebunders, R.; Crucitti, T. The global epidemiology of bacterial vaginosis: A systematic review. Am. J. Obstet. Gynecol. 2013, 209, 505–523. [Google Scholar] [CrossRef]
  17. Sutton, M.Y.; Sternberg, M.; Zaidi, A.; St Louis, M.E.; Markowitz, L.E. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985–2001. Sex. Transm. Dis. 2005, 32, 778–784. [Google Scholar] [CrossRef] [PubMed]
  18. Coudray, M.S.; Madhivanan, P. Bacterial vaginosis-A brief synopsis of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020, 245, 143–148. [Google Scholar] [CrossRef] [PubMed]
  19. Smart, S.; Singal, A.; Mindel, A. Social and sexual risk factors for bacterial vaginosis. Sex. Transm. Infect. 2004, 80, 58–62. [Google Scholar] [CrossRef] [PubMed]
  20. Huang, B.; Fettweis, J.M.; Brooks, J.P.; Jefferson, K.K.; Buck, G.A. The changing landscape of the vaginal microbiome. Clin. Lab. Med. 2014, 34, 747–761. [Google Scholar] [CrossRef]
  21. Hickey, R.J.; Zhou, X.; Pierson, J.D.; Ravel, J.; Forney, L.J. Understanding vaginal microbiome complexity from an ecological perspective. Transl. Res. 2012, 160, 267–282. [Google Scholar] [CrossRef] [PubMed]
  22. Muhleisen, A.L.; Herbst-Kralovetz, M.M. Menopause and the vaginal microbiome. Maturitas 2016, 91, 42–50. [Google Scholar] [CrossRef]
  23. Gajer, P.; Brotman, R.M.; Bai, G.; Sakamoto, J.; Schutte, U.M.; Zhong, X.; Koenig, S.S.; Fu, L.; Ma, Z.S.; Zhou, X.; et al. Temporal dynamics of the human vaginal microbiota. Sci. Transl. Med. 2012, 4, 132ra152. [Google Scholar] [CrossRef]
  24. Lehtoranta, L.; Ala-Jaakkola, R.; Laitila, A.; Maukonen, J. Healthy Vaginal Microbiota and Influence of Probiotics across the Female Life Span. Front. Microbiol. 2022, 13, 819958. [Google Scholar] [CrossRef] [PubMed]
  25. Machado, A.; Cerca, N. Influence of Biofilm Formation by Gardnerella vaginalis and Other Anaerobes on Bacterial Vaginosis. J. Infect. Dis. 2015, 212, 1856–1861. [Google Scholar] [CrossRef] [PubMed]
  26. Elnaggar, J.H.; Lammons, J.W.; Taylor, C.M.; Toh, E.; Ardizzone, C.M.; Dong, A.; Aaron, K.J.; Luo, M.; Tamhane, A.; Lefkowitz, E.J.; et al. Characterization of Vaginal Microbial Community Dynamics in the Pathogenesis of Incident Bacterial Vaginosis, a Pilot Study. Sex. Transm. Dis. 2023, 50, 523–530. [Google Scholar] [CrossRef] [PubMed]
  27. Blackwell, A.L. Vaginal bacterial phaginosis? Sex. Transm. Infect. 1999, 75, 352–353. [Google Scholar] [CrossRef] [PubMed]
  28. Ilhan, Z.E.; Laniewski, P.; Tonachio, A.; Herbst-Kralovetz, M.M. Members of Prevotella Genus Distinctively Modulate Innate Immune and Barrier Functions in a Human Three-Dimensional Endometrial Epithelial Cell Model. J. Infect. Dis. 2020, 222, 2082–2092. [Google Scholar] [CrossRef] [PubMed]
  29. Muzny, C.A.; Laniewski, P.; Schwebke, J.R.; Herbst-Kralovetz, M.M. Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Curr. Opin. Infect. Dis. 2020, 33, 59–65. [Google Scholar] [CrossRef] [PubMed]
  30. Chen, P.C.; Li, P.C.; Ding, D.C. Pelvic inflammatory disease and causative pathogens in older women in a medical center in eastern Taiwan: A retrospective cross-sectional study. PLoS ONE 2021, 16, e0257627. [Google Scholar] [CrossRef] [PubMed]
  31. Larsen, J.M. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 2017, 151, 363–374. [Google Scholar] [CrossRef] [PubMed]
  32. Shah, H.N.; Collins, D.M. Prevotella, a new genus to include Bacteroides melaninogenicus and related species formerly classified in the genus Bacteroides. Int. J. Syst. Bacteriol. 1990, 40, 205–208. [Google Scholar] [CrossRef]
  33. Tett, A.; Pasolli, E.; Masetti, G.; Ercolini, D.; Segata, N. Prevotella diversity, niches and interactions with the human host. Nat. Rev. Microbiol. 2021, 19, 585–599. [Google Scholar] [CrossRef]
  34. Oliver, W.W.; William, B. Notes on some bacterial parasites of the human mucous membranes. J. Infect. Dis. 1921, 28, 341–344. [Google Scholar] [CrossRef]
  35. Sousa, L.G.V.; Almeida, C.; Muzny, C.A.; Cerca, N. Development of a Prevotella bivia PNA probe and a multiplex approach to detect three relevant species in bacterial vaginosis-associated biofilms. NPJ Biofilms Microbiomes 2023, 9, 42. [Google Scholar] [CrossRef]
  36. Usyk, M.; Peters, B.A.; Karthikeyan, S.; McDonald, D.; Sollecito, C.C.; Vazquez-Baeza, Y.; Shaffer, J.P.; Gellman, M.D.; Talavera, G.A.; Daviglus, M.L.; et al. Comprehensive evaluation of shotgun metagenomics, amplicon sequencing, and harmonization of these platforms for epidemiological studies. Cell Rep. Methods 2023, 3, 100391. [Google Scholar] [CrossRef]
  37. Lawson, P.A.; Moore, E.; Falsen, E. Prevotella amnii sp. nov., isolated from human amniotic fluid. Int. J. Syst. Evol. Microbiol. 2008, 58, 89–92. [Google Scholar] [CrossRef]
  38. Haggerty, C.L.; Ness, R.B.; Totten, P.A.; Farooq, F.; Tang, G.; Ko, D.; Hou, X.; Fiedler, T.L.; Srinivasan, S.; Astete, S.G.; et al. Presence and Concentrations of Select Bacterial Vaginosis-Associated Bacteria Are Associated With Increased Risk of Pelvic Inflammatory Disease. Sex. Transm. Dis. 2020, 47, 344–346. [Google Scholar] [CrossRef]
  39. Chen, X.; Lu, Y.; Chen, T.; Li, R. The Female Vaginal Microbiome in Health and Bacterial Vaginosis. Front. Cell. Infect. Microbiol. 2021, 11, 631972. [Google Scholar] [CrossRef]
  40. Soper, D.E.; Wiesenfeld, H.C. The Continued Challenges in the Diagnosis of Acute Pelvic Inflammatory Disease: Focus on Clinically Mild Disease. J. Infect. Dis. 2021, 224 (Suppl. 2), S75–S79. [Google Scholar] [CrossRef]
  41. Könönen, E.; Fteita, D.; Gursoy, U.K.; Gursoy, M. species as oral residents and infectious agents with potential impact on systemic conditions. J. Oral Microbiol. 2022, 14, 2079814. [Google Scholar] [CrossRef] [PubMed]
  42. Prasoodanan, P.K.V.; Sharma, A.K.; Mahajan, S.; Dhakan, D.B.; Maji, A.; Scaria, J.; Sharma, V.K. Western and non-western gut microbiomes reveal new roles of Prevotella in carbohydrate metabolism and mouth-gut axis. NPJ Biofilms Microbiomes 2021, 7, 77. [Google Scholar] [CrossRef] [PubMed]
  43. Hecht, J.L.; Onderdonk, A.; Delaney, M.; Allred, E.N.; Kliman, H.J.; Zambrano, E.; Pflueger, S.M.; Livasy, C.A.; Bhan, I.; Leviton, A.; et al. Characterization of chorioamnionitis in 2nd-trimester C-section placentas and correlation with microorganism recovery from subamniotic tissues. Pediatr. Dev. Pathol. 2008, 11, 15–22. [Google Scholar] [CrossRef]
  44. Toson, B.; Simon, C.; Moreno, I. The Endometrial Microbiome and Its Impact on Human Conception. Int. J. Mol. Sci. 2022, 23, 485. [Google Scholar] [CrossRef] [PubMed]
  45. Kononen, E.; Gursoy, U.K. Oral Species and Their Connection to Events of Clinical Relevance in Gastrointestinal and Respiratory Tracts. Front. Microbiol. 2022, 12, 798763. [Google Scholar] [CrossRef] [PubMed]
  46. Petrina, M.A.B.; Cosentino, L.A.; Wiesenfeld, H.C.; Darville, T.; Hillier, S.L. Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. Anaerobe 2019, 56, 61–65. [Google Scholar] [CrossRef] [PubMed]
  47. Austin, M.N.; Beigi, R.H.; Meyn, L.A.; Hillier, S.L. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J. Clin. Microbiol. 2005, 43, 4492–4497. [Google Scholar] [CrossRef] [PubMed]
  48. Persson, R.; Hitti, J.; Verhelst, R.; Vaneechoutte, M.; Persson, R.; Hirschi, R.; Weibel, M.; Rothen, M.; Temmerman, M.; Paul, K.; et al. The vaginal microflora in relation to gingivitis. BMC Infect. Dis. 2009, 9, 6. [Google Scholar] [CrossRef]
  49. Haggerty, C.L.; Hillier, S.L.; Bass, D.C.; Ness, R.B.; PID Evaluation; Clinical Health (PEACH) Study Investigators. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin. Infect. Dis. 2004, 39, 990–995. [Google Scholar] [CrossRef] [PubMed]
  50. Marietta, E.; Horwath, I.; Meyer, S.; Khaleghi-Rostamkolaei, S.; Norman, E.; Luckey, D.; Balakrishnan, B.; Mangalam, A.; Choung, R.S.; Taneja, V.; et al. Administration of Human Derived Upper gut Commensal Prevotella histicola delays the onset of type 1 diabetes in NOD mice. BMC Microbiol. 2022, 22, 8. [Google Scholar] [CrossRef]
  51. Webb, K.A.; Olagoke, O.; Baird, T.; Neill, J.; Pham, A.; Wells, T.J.; Ramsay, K.A.; Bell, S.C.; Sarovich, D.S.; Price, E.P. Genomic diversity and antimicrobial resistance of Prevotella species isolated from chronic lung disease airways. Microb. Genom. 2022, 8, 000754. [Google Scholar] [CrossRef] [PubMed]
  52. Anani, H.; Guilhot, E.; Andrieu, C.; Fontanini, A.; Raoult, D.; Fournier, P.E. Prevotella ihumii sp. nov., a new bacterium isolated from a stool specimen of a healthy woman. New Microbes New Infect. 2019, 32, 100607. [Google Scholar] [CrossRef]
  53. Balle, C.; Esra, R.; Havyarimana, E.; Jaumdally, S.Z.; Lennard, K.; Konstantinus, I.N.; Barnabas, S.L.; Happel, A.U.; Gill, K.; Pidwell, T.; et al. Relationship between the Oral and Vaginal Microbiota of South African Adolescents with High Prevalence of Bacterial Vaginosis. Microorganisms 2020, 8, 1004. [Google Scholar] [CrossRef]
  54. Park, S.N.; Lim, Y.K.; Shin, J.H.; Jo, E.; Chang, Y.H.; Shin, Y.; Paek, J.; Ji, S.; Kim, H.; Kook, J.K. Prevotella koreensis sp. nov., Isolated from Human Subgingival Dental Plaque of Periodontitis Lesion. Curr. Microbiol. 2019, 76, 1055–1060. [Google Scholar] [CrossRef] [PubMed]
  55. Diop, K.; Diop, A.; Levasseur, A.; Mediannikov, O.; Robert, C.; Armstrong, N.; Couderc, C.; Bretelle, F.; Raoult, D.; Fournier, P.E.; et al. Microbial Culturomics Broadens Human Vaginal Flora Diversity: Genome Sequence and Description of Prevotella lascolaii sp. nov. Isolated from a Patient with Bacterial Vaginosis. OMICS 2018, 22, 210–222. [Google Scholar] [CrossRef] [PubMed]
  56. Mehmood, M.; Jaffar, N.A.; Nazim, M.; Khasawneh, F.A. Bacteremic skin and soft tissue infection caused by Prevotella loescheii. BMC Infect. Dis. 2014, 14, 162. [Google Scholar] [CrossRef]
  57. Briselden, A.M.; Moncla, B.J.; Stevens, C.E.; Hillier, S.L. Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. J. Clin. Microbiol. 1992, 30, 663–666. [Google Scholar] [CrossRef] [PubMed]
  58. Kuete Yimagou, E.; Mekhalif, F.; Lamine Tall, M.; Baudoin, J.P.; Raoult, D.; Bou Khalil, J.Y. Prevotella marseillensis sp. nov., a new bacterium isolated from a patient with recurrent Clostridium difficile infection. New Microbes New Infect. 2019, 32, 100606. [Google Scholar] [CrossRef] [PubMed]
  59. Ndongo, S.; Lagier, J.C.; Fournier, P.E.; Raoult, D.; Khelaifia, S. “Prevotellamassilia timonensis”, a new bacterial species isolated from the human gut. New Microbes New Infect. 2016, 13, 102–103. [Google Scholar] [CrossRef] [PubMed]
  60. Duerden, B.I. Black-pigmented gram-negative anaerobes in genito-urinary tract and pelvic infections. FEMS Immunol. Med. Microbiol. 1993, 6, 223–227. [Google Scholar] [CrossRef] [PubMed]
  61. Precup, G.; Vodnar, D.C. Gut Prevotella as a possible biomarker of diet and its eubiotic versus dysbiotic roles: A comprehensive literature review. Brit. J. Nutr. 2019, 122, 131–140. [Google Scholar] [CrossRef] [PubMed]
  62. Afouda, P.; Ndongo, S.; Khelaifia, S.; Labas, N.; Cadoret, F.; Di Pinto, F.; Delerce, J.; Raoult, D.; Million, M. Noncontiguous finished genome sequence and description of Prevotella phocaeensis sp. nov., a new anaerobic species isolated from human gut infected by Clostridium difficile. New Microbes New Infect. 2017, 15, 117–127. [Google Scholar] [CrossRef]
  63. Sakamoto, M.; Ohkusu, K.; Masaki, T.; Kako, H.; Ezaki, T.; Benno, Y. Prevotella pleuritidis sp. nov., isolated from pleural fluid. Int. J. Syst. Evol. Microbiol. 2007, 57 Pt 8, 1725–1728. [Google Scholar] [CrossRef]
  64. Asif, A.A.; Roy, M.; Ahmad, S. Rare case of Prevotella pleuritidis lung abscess. BMJ Case Rep. 2020, 13, e235960. [Google Scholar] [CrossRef] [PubMed]
  65. Efimov, B.A.; Chaplin, A.V.; Shcherbakova, V.A.; Suzina, N.E.; Podoprigora, I.V.; Shkoporov, A.N. Prevotella rara sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 2018, 68, 3818–3825. [Google Scholar] [CrossRef] [PubMed]
  66. Hammad, M.I.; Conrads, G.; Abdelbary, M.M.H. Isolation, identification, and significance of salivary Veillonella spp., Prevotella spp., and Prevotella salivae in patients with inflammatory bowel disease. Front. Cell. Infect. Microbiol. 2023, 13, 1278582. [Google Scholar] [CrossRef] [PubMed]
  67. van Teijlingen, N.H.; Helgers, L.C.; Zijlstra-Willems, E.M.; van Hamme, J.L.; Ribeiro, C.M.S.; Strijbis, K.; Geijtenbeek, T.B.H. Vaginal dysbiosis associated-bacteria Megasphaera elsdenii and Prevotella timonensis induce immune activation via dendritic cells. J. Reprod. Immunol. 2020, 138, 103085. [Google Scholar] [CrossRef] [PubMed]
  68. Marrazzo, J.M.; Hillier, S.L. Sexually Transmitted Diseases, 2nd ed.; Academic Press: Cambridge, MA, USA, 2013; ISBN 9780123910592. [Google Scholar]
  69. Muzny, C.A.; Taylor, C.M.; Swords, W.E.; Tamhane, A.; Chattopadhyay, D.; Cerca, N.; Schwebke, J.R. An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. J. Infect. Dis. 2019, 220, 1399–1405. [Google Scholar] [CrossRef] [PubMed]
  70. Holdeman, L.V.; Johnson, J.L. Bacteroides disiens sp. nov. and Bacteroides bivius sp. nov. from Human Clinical Infections. Int. J. Syst. Evol. Microbiol. 1977, 27, 337–345. [Google Scholar] [CrossRef]
  71. Muzny, C.A.; Blanchard, E.; Taylor, C.M.; Aaron, K.J.; Talluri, R.; Griswold, M.E.; Redden, D.T.; Luo, M.; Welsh, D.A.; Van Der Pol, W.J.; et al. Identification of Key Bacteria Involved in the Induction of Incident Bacterial Vaginosis: A Prospective Study. J. Infect. Dis. 2018, 218, 966–978. [Google Scholar] [CrossRef]
  72. Srinivasan, S.; Hoffman, N.G.; Morgan, M.T.; Matsen, F.A.; Fiedler, T.L.; Hall, R.W.; Ross, F.J.; McCoy, C.O.; Bumgarner, R.; Marrazzo, J.M.; et al. Bacterial communities in women with bacterial vaginosis: High resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS ONE 2012, 7, e37818. [Google Scholar] [CrossRef]
  73. Gilbert, N.M.; Lewis, W.G.; Li, G.; Sojka, D.K.; Lubin, J.B.; Lewis, A.L. Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis. J. Infect. Dis. 2019, 220, 1099–1108. [Google Scholar] [CrossRef]
  74. Smayevsky, J.; Canigia, L.F.; Lanza, A.; Bianchini, H. Vaginal microflora associated with bacterial vaginosis in nonpregnant women: Reliability of sialidase detection. Infect. Dis. Obstet. Gynecol. 2001, 9, 17–22. [Google Scholar] [CrossRef]
  75. Plummer, E.L.; Sfameni, A.M.; Vodstrcil, L.A.; Danielewski, J.A.; Murray, G.L.; Fehler, G.; Fairley, C.K.; Garland, S.M.; Chow, E.P.F.; Hocking, J.S.; et al. Prevotella and Gardnerella Are Associated with Treatment Failure Following First-line Antibiotics for Bacterial Vaginosis. J. Infect. Dis. 2023, 228, 646–656. [Google Scholar] [CrossRef] [PubMed]
  76. Glazunova, O.O.; Launay, T.; Raoult, D.; Roux, V. Prevotella timonensis sp. nov., isolated from a human breast abscess. Int. J. Syst. Evol. Microbiol. 2007, 57 Pt 4, 883–886. [Google Scholar] [CrossRef] [PubMed]
  77. Sharma, G.; Garg, N.; Hasan, S.; Shirodkar, S. Prevotella: An insight into its characteristics and associated virulence factors. Microb. Pathogenesis 2022, 169, 105673. [Google Scholar] [CrossRef] [PubMed]
  78. Pybus, V.; Onderdonk, A.B. Evidence for a commensal, symbiotic relationship between Gardnerella vaginalis and Prevotella bivia involving ammonia: Potential significance for bacterial vaginosis. J. Infect. Dis. 1997, 175, 406–413. [Google Scholar] [CrossRef]
  79. Petrina, M.A.B.; Cosentino, L.A.; Rabe, L.K.; Hillier, S.L. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe 2017, 47, 115–119. [Google Scholar] [CrossRef]
  80. Pelayo, P.; Hussain, F.A.; Werlang, C.A.; Wu, C.; Woolston, B.M.; Ribbeck, K.; Kwon, D.S.; Balskus, E.P. Prevotella are major contributors of sialidases in the human vaginal microbiome. bioRxiv 2024, 1, 574895. [Google Scholar]
  81. Veloo, A.C.M.; Chlebowicz, M.; Winter, H.L.J.; Bathoorn, D.; Rossen, J.W.A. Three metronidazole-resistant Prevotella bivia strains harbour a mobile element, encoding a novel nim gene, nimK, and an efflux small MDR transporter. J. Antimicrob. Chemother. 2018, 73, 2687–2690. [Google Scholar] [CrossRef]
  82. Filardo, S.; Di Pietro, M.; Tranquilli, G.; Latino, M.A.; Recine, N.; Porpora, M.G.; Sessa, R. Selected Immunological Mediators and Cervical Microbial Signatures in Women with Chlamydia trachomatis Infection. mSystems 2019, 4, 10–1128. [Google Scholar] [CrossRef]
  83. Dunlop, A.L.; Satten, G.A.; Hu, Y.J.; Knight, A.K.; Hill, C.C.; Wright, M.L.; Smith, A.K.; Read, T.D.; Pearce, B.D.; Corwin, E.J. Vaginal Microbiome Composition in Early Pregnancy and Risk of Spontaneous Preterm and Early Term Birth Among African American Women. Front. Cell. Infect. Microbiol. 2021, 11, 641005. [Google Scholar] [CrossRef]
  84. Margolis, E.; Fredricks, D.N. Bacterial vaginosis-associated bacteria. In Molecular Medical Microbiology, 2nd ed.; Academic Press: Cambridge, MA, USA, 2015; pp. 1487–1496. [Google Scholar]
  85. Mitra, A.; MacIntyre, D.A.; Ntritsos, G.; Smith, A.; Tsilidis, K.K.; Marchesi, J.R.; Bennett, P.R.; Moscicki, A.B.; Kyrgiou, M. The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat. Commun. 2020, 11, 1999. [Google Scholar] [CrossRef]
  86. Wright, D.P.; Rosendale, D.I.; Roberton, A.M. enzymes involved in mucin oligosaccharide degradation and evidence for a small operon of genes expressed during growth on mucin. FEMS Microbiol. Lett. 2000, 190, 73–79. [Google Scholar] [CrossRef] [PubMed]
  87. Ferreira, C.S.T.; Marconi, C.; Parada, C.M.G.L.; Ravel, J.; Silva, M.G.D. Sialidase Activity in the Cervicovaginal Fluid Is Associated with Changes in Bacterial Components of Deprived Microbiota. Front. Cell. Infect. Microbiol. 2022, 11, 813520. [Google Scholar] [CrossRef]
  88. Miyagi, T.; Yamaguchi, K. Mammalian sialidases: Physiological and pathological roles in cellular functions. Glycobiology 2012, 22, 880–896. [Google Scholar] [CrossRef] [PubMed]
  89. Chen, L.; Li, J.; Xiao, B. The role of sialidases in the pathogenesis of bacterial vaginosis and their use as a promising pharmacological target in bacterial vaginosis. Front. Cell. Infect. Microbiol. 2024, 14, 1367233. [Google Scholar] [CrossRef] [PubMed]
  90. Hardy, L.; Cerca, N.; Jespers, V.; Vaneechoutte, M.; Crucitti, T. Bacterial biofilms in the vagina. Res. Microbiol. 2017, 168, 865–874. [Google Scholar] [CrossRef] [PubMed]
  91. Weir, C.B.; Le, J.K. Metronidazole; StatPearls: Treasure Island, FL, USA, 2023. [Google Scholar]
  92. Sousa, L.G.V.; Pereira, S.A.; Cerca, N. Fighting polymicrobial biofilms in bacterial vaginosis. Microb. Biotechnol. 2023, 16, 1423–1437. [Google Scholar] [CrossRef] [PubMed]
  93. Bautista, C.T.; Wurapa, E.; Sateren, W.B.; Morris, S.; Hollingsworth, B.; Sanchez, J.L. Bacterial vaginosis: A synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil. Med. Res. 2016, 3, 4. [Google Scholar] [CrossRef] [PubMed]
  94. Randis, T.M.; Ratner, A.J. Gardnerella and Prevotella: Co-conspirators in the Pathogenesis of Bacterial Vaginosis. J. Infect. Dis. 2019, 220, 1085–1088. [Google Scholar] [CrossRef] [PubMed]
  95. Si, J.; You, H.J.; Yu, J.; Sung, J.; Ko, G. as a Hub for Vaginal Microbiota under the Influence of Host Genetics and Their Association with Obesity. Cell Host Microbe 2017, 21, 97–105. [Google Scholar] [CrossRef]
  96. Gibbs, R.S. Chorioamnionitis and Bacterial Vaginosis. Am. J. Obstet. Gynecol. 1993, 169, 460–462. [Google Scholar] [CrossRef]
  97. Haggerty, C.L.; Totten, P.A.; Tang, G.; Astete, S.G.; Ferris, M.J.; Norori, J.; Bass, D.C.; Martin, D.H.; Taylor, B.D.; Ness, R.B. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex. Transm. Infect. 2016, 92, 441–446. [Google Scholar] [CrossRef] [PubMed]
  98. Kimura, F.; Takebayashi, A.; Ishida, M.; Nakamura, A.; Kitazawa, J.; Morimune, A.; Hirata, K.; Takahashi, A.; Tsuji, S.; Takashima, A.; et al. Review: Chronic endometritis and its effect on reproduction. J. Obstet. Gynaecol. Res. 2019, 45, 951–960. [Google Scholar] [CrossRef] [PubMed]
  99. Burnett, A.M.; Anderson, C.P.; Zwank, M.D. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am. J. Emerg. Med. 2012, 30, 1114–1117. [Google Scholar] [CrossRef] [PubMed]
  100. Workowski, K.A.; Bolan, G.A.; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm. Rep. 2015, 64, 1–137. [Google Scholar] [PubMed]
  101. Ness, R.B.; Kip, K.E.; Hillier, S.L.; Soper, D.E.; Stamm, C.A.; Sweet, R.L.; Rice, P.; Richter, H.E. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am. J. Epidemiol. 2005, 162, 585–590. [Google Scholar] [CrossRef] [PubMed]
  102. Mitchell, C.M.; Anyalechi, G.E.; Cohen, C.R.; Haggerty, C.L.; Manhart, L.E.; Hillier, S.L. Etiology and Diagnosis of Pelvic Inflammatory Disease: Looking Beyond Gonorrhea and Chlamydia. J. Infect. Dis. 2021, 224 (Suppl. 2), S29–S35. [Google Scholar] [CrossRef] [PubMed]
  103. Wang, J.F.; Li, Z.Z.; Ma, X.L.; Du, L.F.; Jia, Z.; Cui, X.; Yu, L.Q.; Yang, J.; Xiao, L.W.; Zhang, B.; et al. Translocation of vaginal microbiota is involved in impairment and protection of uterine health. Nat. Commun. 2021, 12, 4191. [Google Scholar] [CrossRef] [PubMed]
  104. Wiesenfeld, H.C.; Meyn, L.A.; Darville, T.; Macio, I.S.; Hillier, S.L. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, with or without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. Clin. Infect. Dis. 2021, 72, 1181–1189. [Google Scholar] [CrossRef] [PubMed]
  105. Walker, C.K.; Workowski, K.A.; Washington, A.E.; Soper, D.; Sweet, R.L. Anaerobes in pelvic inflammatory disease: Implications for the Centers for Disease Control and Prevention’s guidelines for treatment of sexually transmitted diseases. Clin. Infect. Dis. 1999, 28 (Suppl. 1), S29–S36. [Google Scholar] [CrossRef]
  106. Urushiyama, D.; Ohnishi, E.; Suda, W.; Kurakazu, M.; Kiyoshima, C.; Hirakawa, T.; Miyata, K.; Yotsumoto, F.; Nabeshima, K.; Setoue, T.; et al. Vaginal microbiome as a tool for prediction of chorioamnionitis in preterm labor: A pilot study. Sci. Rep. 2021, 11, 18971. [Google Scholar] [CrossRef]
  107. Doyle, R.M.; Harris, K.; Kamiza, S.; Harjunmaa, U.; Ashorn, U.; Nkhoma, M.; Dewey, K.G.; Maleta, K.; Ashorn, P.; Klein, N. Bacterial communities found in placental tissues are associated with severe chorioamnionitis and adverse birth outcomes. PLoS ONE 2017, 12, e0180167. [Google Scholar] [CrossRef] [PubMed]
Pathogens 13 00364 g001
Figure 1. FISH of pure culture bacterial species. (A) DAPI, GFP, and TX RED stain featuring three common BV-associated bacteria: P. bivia (GFP), Gardnerella vaginalis (TX RED), and Fannyhessea vaginae (white). (B) GFP featuring P. bivia in the same culture as (A) to highlight its appearance and prevalence within the culture. Images taken at a 60× magnification at high resolution. Figure courtesy of Chaoling Dong, PhD. Abbreviations: peptide nucleic acid fluorescent in situ hybridization (PNA-FISH), 4′,6-diamidino-2-phenylindole (DAPI), green fluorescent protein (GFP), and Texas red (TX RED).
Figure 1. FISH of pure culture bacterial species. (A) DAPI, GFP, and TX RED stain featuring three common BV-associated bacteria: P. bivia (GFP), Gardnerella vaginalis (TX RED), and Fannyhessea vaginae (white). (B) GFP featuring P. bivia in the same culture as (A) to highlight its appearance and prevalence within the culture. Images taken at a 60× magnification at high resolution. Figure courtesy of Chaoling Dong, PhD. Abbreviations: peptide nucleic acid fluorescent in situ hybridization (PNA-FISH), 4′,6-diamidino-2-phenylindole (DAPI), green fluorescent protein (GFP), and Texas red (TX RED).
Pathogens 13 00364 g001
Pathogens 13 00364 g002
Figure 2. P. bivia colonies grown on a blood agar plate after 72 h. Colonies are shiny and gray in color. Figure courtesy of Sheridan D. George.
Figure 2. P. bivia colonies grown on a blood agar plate after 72 h. Colonies are shiny and gray in color. Figure courtesy of Sheridan D. George.
Pathogens 13 00364 g002
Table 1. Prevotella spp. associated with human hosts and their respective organ systems. Listed are the most common/relevant clinical syndromes and organ system involvements as Prevotella spp. are found in many infections.
Table 1. Prevotella spp. associated with human hosts and their respective organ systems. Listed are the most common/relevant clinical syndromes and organ system involvements as Prevotella spp. are found in many infections.
Species NamePrimary Clinical SyndromeCommon Organ System Involvement
P. amniiBV, Endometritis, PIDVagina, Amniotic fluid [37,38,39,40]
P. aurantiacaPeriodontal diseaseOral [41]
P. baroniaeOral disease(s) 1Oral, Brain abscess [41]
P. bergensisGut dysbiosis/UnknownOral, Breast abscess, Skin/soft tissue, Gut [41,42]
P. biviaBV, Endometritis, PID,
Chorioamnionitis		Vagina, Skin/soft tissue [33,43,44]
P. brunneaUnknownSkin/soft tissue [45]
P. buccaeOral disease(s) 1Oral [41]
P. buccalisOral disease(s) 1, BV, Endometritis, PIDVagina, Oral, Gut [33,41,46]
P. coloransUnknownSkin/soft tissue [45]
P. copriGut dysbiosis, Rheumatoid arthritisGut [31]
P. corporisBVVagina, Oral, Gut [33,47]
P. dentalisOral disease(s) 1Oral [41]
P. denticolaOral disease(s) 1, BV, Endometritis, PIDVagina, Oral [28,41,46]
P. disiensBV, Endometritis, PID, GingivitisVagina, Gut, Bartholin abscess, Oral [28,33,48,49]
P. enoecaPeriodontal diseaseOral [41]
P. fuscaPeriodontal diseaseOral [41]
P. heparinolyticaPeriodontal abscessesOral, Brain abscess [41]
P. histicolaOral disease(s) 1Vagina, Oral, Gut, Airways [33,41,50,51]
P. ihumiiGut microbiome/UnknownGut [52]
P. intermediaOral disease(s) 1Oral, Empyema, Gut [33,41,53]
P. jejuniGut dysbiosis/UnknownGut, Oral [41]
P. koreensisOral Disease(s) 1, Gut dysbiosisOral, Gut [42,54]
P. lascolaiiBVVagina, Gut [42,55]
P. loescheiiOral disease(s) 1, BVOral, Gut, Skin/soft tissue [41,56,57]
P. maculosaOral disease(s) 1Oral [41]
P. marseillensisGut dysbiosis/UnknownGut [58]
P. marshiiOral disease(s) 1Oral [41]
P. massilia timonensisGut microbiome/UnknownGut [59]
P. melaninogenicaOral disease(s) 1, BV, Endometritis, PIDVagina, Oral, Sputum, Gut [33,41,60]
P. micansPeri-implantitisOral, Gut [41,61]
P. multiformisOral disease(s) 1Oral, Gut [41,45]
P. multisaccharivoraxOral disease(s) 1Oral [41]
P. nanceiensisUnknownBlood, Oral, Airways, Gut [45]
P. nigrescensOral disease(s) 1Oral, Gut [31,45]
P. oralisOral disease(s) 1, BV, PIDVagina, Gut, Oral [30,41,42,47]
P. orisOral disease(s) 1Oral, Airways, Gut [41,45]
P. oulorumOral disease(s) 1Oral [41]
P. pallensOral disease(s) 1Oral, Gut [41,45]
P. phocaeensisGut dysbiosisGut [62]
P. pleuritidisPleuritisPleural fluid, Lung abscess [63,64]
P. raraGut microbiome/UnknownGut [65]
P. saccharolyticaPeri-implant mucositisOral [41]
P. salivaeOral disease(s) 1, Gut dysbiosisOral, Gut [41,66]
P. scoposOral disease(s) 1Oral [41]
P. shahiiOral disease(s) 1Oral [41]
P. stercoreaGut microbiome/dysbiosisGut [31]
P. timonensisBV, Endometritis, PIDVagina, Breast abscess [38,46,67]
P. veroralisOral disease(s) 1Oral, Gut, Airways [41,45]
1 Oral diseases include, but are not limited to periodontitis, periodontal disease, periodontal abscess, endodontic infection, dental caries, halitosis, and peri-implantitis [41]. Oral Prevotella spp. may appear in FGTIs depending upon a woman’s sexual activities [33]. Abbreviations: BV: bacterial vaginosis, and PID: pelvic inflammatory disease.
Table 2. Morphological and physiological differences between key Prevotella spp. involved in FGTIs.
Table 2. Morphological and physiological differences between key Prevotella spp. involved in FGTIs.
CharacteristicP. biviaP. amniiP. timonensis
Genomic length (Mb)2.49 ± 0.08 [33]2.4 ± 0.03 [33]3.09 ± 0.16 [33]
Colony appearanceCircular, gray, shiny, circular colonies
(Figure 2)		Circular, white, smooth, shiny, circular colonies [37]Circular, light gray, smooth, shiny colonies [76]
Colony size<1 mm (Figure 2)<1 mm [37]1–2 mm [76]
Virulence factorsSialidase, ammonia, mucin expression, antibiotic resistance
[28,69,77,78] 		Antibiotic resistance, sialidase [79,80]Dramatic sialidase secretion, mucin expression, antibiotic resistance [28,79]
Biofilm appearance in vivoDispersed biofilm, crevice colonization [28]UnknownElongated microvilli, dispersed biofilm [28]
FGTIBV, Endometritis, PID, ChorioamnionitisBV, Endometritis, PIDBV, Endometritis, PID
Antibiotic resistanceYes (Clindamycin, Ceftriaxone, Metronidazole) [79,81]Yes (Clindamycin) [79]Yes (Clindamycin) [79]
Abbreviations: BV: bacterial vaginosis; PID: pelvic inflammatory disease.
Table 3. Prevotella spp. virulence factors in vitro, in mice models, and in humans.
Table 3. Prevotella spp. virulence factors in vitro, in mice models, and in humans.
Prevotella SpeciesIn vitroMiceHumans
P. biviaAntibiotic resistance, sialidase, ammonia, cell crevice colonization [28,78,79]Sialidase,
ascension [73]		Sialidase, ammonia [57], antibiotic resistance [81]
P. amniiAntibiotic resistance [79]UnknownSialidase [80]
P. timonensisAntibiotic resistance [79], elongated microvilli, mucin activity, dramatic sialidase secretion, biofilm dispersion [28]UnknownSialidase [80]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

George, S.D.; Van Gerwen, O.T.; Dong, C.; Sousa, L.G.V.; Cerca, N.; Elnaggar, J.H.; Taylor, C.M.; Muzny, C.A. The Role of Prevotella species in Female Genital Tract Infections. Pathogens 2024, 13, 364. https://doi.org/10.3390/pathogens13050364

AMA Style

George SD, Van Gerwen OT, Dong C, Sousa LGV, Cerca N, Elnaggar JH, Taylor CM, Muzny CA. The Role of Prevotella species in Female Genital Tract Infections. Pathogens. 2024; 13(5):364. https://doi.org/10.3390/pathogens13050364

Chicago/Turabian Style

George, Sheridan D., Olivia T. Van Gerwen, Chaoling Dong, Lúcia G. V. Sousa, Nuno Cerca, Jacob H. Elnaggar, Christopher M. Taylor, and Christina A. Muzny. 2024. "The Role of Prevotella species in Female Genital Tract Infections" Pathogens 13, no. 5: 364. https://doi.org/10.3390/pathogens13050364

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop